Out of 400+ applications, we've selected 25 finalists who will pitch live on May 6. These ventures represent 11 Harvard schools and are one step closer to winning a share of $500,000+ in Bertarelli Foundation funding.
2026
President’s Innovation Challenge
-
NuCyRNA Therapeutics
Redefining RNA-targeting therapeutics, starting in neurodegenerative diseases.
![Nucyrna team lead]()
-
PathCision Medicine
Developing tissue-informed precision therapeutics with superior delivery and efficacy for cancer and other complex diseases.
![]()
-
Promakhos Therapeutics Inc.
Developing oral, non-immunosuppressive, small molecules to cure chronic inflammatory disorders.
![]()
